1. Optimizing Joint Health in Hemophilia

2. This program will include a discussion of investigational agents not approved by the FDA for use in the United States.

3. Introduction

4. Prophylaxis Studies and Joint Health

5. Challenges to Prophylaxis

6. Introducing Prophylaxis

7. Inhibitors

8. Discussing Prophylaxis Risk With Patients

9. Overview of EHL Factor Concentrates

10. Choosing Factor Concentrates

11. Monitoring Response

12. Concerns With Prophylaxis

13. Is It Possible to Stop Prophylaxis?

14. Functional Assessment Tools

15. Objective Assessment: Imaging

16. Global Implications

17. Concluding Remarks

18. Abbreviations

19. Abbreviations (cont)